Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
| العنوان: | Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes |
|---|---|
| المؤلفون: | Luis-Emilio Garcia-Perez, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Katie D. Stewart, Katelyn N. Cutts |
| المصدر: | Quality of Life Research |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Type 2 diabetes, Article, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, Route of administration, 0302 clinical medicine, Utility, Internal medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, GLP-1 RA, Glucagon-like peptide 1 receptor, Aged, business.industry, 030503 health policy & services, Public health, Semaglutide, Treatment process, Public Health, Environmental and Occupational Health, Middle Aged, medicine.disease, Treatment process utility, Diabetes Mellitus, Type 2, Quality of Life, Glucagon-like peptide-1 receptor agonist, Female, Dulaglutide, 0305 other medical science, business, Dose Frequency, (4–6): Health state utility, medicine.drug |
| الوصف: | Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D). Methods Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection. Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral semaglutide, 0.878 for dulaglutide injection, and 0.859 for semaglutide injection (with higher scores indicating greater preference). All pairwise comparisons found statistically significant differences between utilities (p Conclusions Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient preferences for treatment process when selecting medications for patients in clinical settings. |
| تدمد: | 1573-2649 0962-9343 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15aa003fafb860c63db79688923fe1Test https://doi.org/10.1007/s11136-021-02808-2Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6c15aa003fafb860c63db79688923fe1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15732649 09629343 |
|---|